Rotate your device to portrait mode.
Hematogenix® announces the opening of their newest facility in Shanghai, China furthering their commitment to be a global leader in the field of cancer research and diagnostic testing. China's growing population is attractive to the pharmaceutical industry as the race to develop new therapies for the oncology market continues. The decision to invest in China's rapidly growing research and development market positions Hematogenix® as a global contributor to the advancement of oncology research. Hematogenix® is one of the companies that is responding to recent advancements that have occurred in China's clinical trials regulations.
"Our decision to expand to China supports the global science community," said Hytham Al-Masri, M.D., CEO and Founder of Hematogenix®. "This investment is in-line with our mission to make it possible for scientists to do world-class research globally. The multinational pharma partners we support are starting to make China a priority. We are providing a solution to support their goals through our Pharma Services expansion which now includes four locations, the Americas, Europe, China and Asia-Pacific."
Hematogenix® is a specialized CRO with a global presence focused on cancer research and diagnostics. The company employs a team of top scientists, board-certified clinical, anatomic, and hematopathologists from around the world. Hematogenix® offers an array of biomarker development and testing services which navigate the complexities of human subject clinical trials. The company's clinical laboratories are CAP, and CLIA certified, GCP-compliant and serve both the pharmaceutical industry as a specialized clinical research organization and the oncology industry as a clinical and anatomical testing provider. Learn more about Hematogenix's comprehensive biomarker development and testing services at www.hematogenix.com.
Hematogenix® is a registered trademark of Hematogenix® Laboratory Services, LLC.